No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Bicara Therapeutics Inc. Common Stock (BCAX) stock was $17.29 as of Oct 5, 2026, 4:00 PM EDT, down 1.93% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -4.1%
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors.
Biotechnology · Boston, MA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.84
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.82
vs Estimate
$-0.83
Revenue
$0.00
vs Estimate
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BCAX | $1.14B | $17.29 | -1.93% | -4.12% | N/A | N/A | N/A |
| 2HROW | $1.14B | $30.58 | +0.33% | -32.56% | +27.66% | +23.49% | vs BCAX |
| 3CSTL | $1.12B | $36.65 | +3.07% | +60.94% | -10.28% | N/A | vs BCAX |
| 4AMPH | $1.12B | $25.37 | -0.24% | -5.13% | +6.13% | +2.47% | vs BCAX |
| 5GDRX | $1.16B | $3.36 | +2.44% | -25.72% | -39.98% | N/A | vs BCAX |
| 6IRMD | $1.11B | $86.47 | +1.25% | +22.96% | +24.06% | +24.37% | vs BCAX |
forward FY estimate
N/A
Consensus Rating
Based on 12 analysts
Average Price Target
$35.50
+105.3% upside
Low
$20.00
Current
$17.29
High
$45.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.85 | $-0.82 | $-0.79 | 9 |
| Quarter ending Dec 2026 | $-0.93 | $-0.86 | $-0.82 | 8 |
| Quarter ending Mar 2027 | $-0.88 | $-0.88 | $-0.88 | 3 |
| Quarter ending Jun 2027 | $-0.91 | $-0.91 | $-0.91 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.61 | $-3.42 | $-3.34 | 10 |
| FY 2027 | $-3.89 | $-3.62 | $-3.36 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
